INS and type 1 diabetes mellitus: In addition, it was interesting to note that more and more research results suggested that dapagliflozin was a promising adjunct treatment to insulin which improves glycemic control in patients with inadequately controlled T1DM (Dandona et al., 2017; Mathieu et al., 2018; Parkinson et al., 2019; Araki et al., 2020; Araki et al., 2021; Biester et al., 2021).